Assessment of the Expression Level of B-Cell Lymphoma 6 (BCL6) in Peripheral Blood CD38+ B Lymphocytes in Patients with Common Variable Immunodeficiency (CVID)

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Immunology and Allergy, The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran

4 Associate Professor, Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 Assistant Professor, Primary Immunodeficiency Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

immunodeficiency, is a heterogeneous set of immunological abnormalities including decreased serum levels of antibodies, and impaired antibody response to infections or vaccination. The syndrome includes impaired B-cell maturation, impaired somatic hypermutation, reduced numbers of circulating memory B cells, and absent or reduced plasma cells. B cell lymphoma 6 (BCL6) is a transcription factor which is important for the evolution and proliferation of B cells. This study aimed to investigate the expression of BCL6 in peripheral blood CD38+ B lymphocytes in patients with CVID.Methods: Blood samples were collected from 14 patients with CVID under substitutive immunoglobulin (Ig) therapy before immunoglobulin infusion and 14 normal controls. Then, peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque density centrifugation. CD19+ B lymphocytes were purified from PBMCs by positive selection using B-cell isolation kit. Flow cytometery method was employed to determine the expression of the BCL6 in CD38+ B cells.Findings: The expression of BCL6 in CD38 +B lymphocytes was 1.51% and 0.58% in patients and healthy subjects, respectively; the difference was not statistically significant (P > 0.05).Conclusion: The results showed that there is no significant difference in the mean expression of BCL6 of the CD38+ B cells in patients with CVID, compared with control group. However, the average BCL6 expression of CD38+ B lymphocytes in patients was more than control group.

Keywords

References

  1. Kralovicova J, Hammarstrom L, Plebani A, Webster AD, Vorechovsky I. Fine-scale mapping at IGAD1 and genome-wide genetic linkage analysis implicate HLA-DQ/DR as a major susceptibility locus in selective IgA deficiency and common variable immunodeficiency. J Immunol 2003; 170(5): 2765-75.
  2. Taubenheim N, von Hornung M, Durandy A, Warnatz K, Corcoran L, Peter HH, et al. Defined blocks in terminal plasma cell differentiation of common variable immunodeficiency patients. J Immunol 2005; 175(8): 5498-503.
  3. Kokron CM, Errante PR, Barros MT, Baracho GV, Camargo MM, Kalil J, et al. Clinical and laboratory aspects of common variable immunodeficiency. An Acad Bras Cienc 2004; 76(4): 707-26.
  4. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Galicier L, Lepelletier Y, Webster D, et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood 2004; 104(8): 2441-3.
  5. Farrant J, Spickett G, Matamoros N, Copas D, Hernandez M, North M, et al. Study of B and T cell phenotypes in blood from patients with common variable immunodeficiency (CVID). Immunodeficiency 1994; 5(2): 159-69.
  6. Schroeder HW, Jr., Schroeder HW 3rd, Sheikh SM. The complex genetics of common variable immunodeficiency. J Investig Med 2004; 52(2): 90-103.
  7. Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 2008; 26: 133-69.
  8. Ahn S, Cunningham-Rundles C. Role of B cells in common variable immune deficiency. Expert Rev Clin Immunol 2009; 5(5): 557-64.
  9. Yong PF, Thaventhiran JE, Grimbacher B. "A rose is a rose is a rose," but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv Immunol 2011; 111: 47-107.
  10. Jacquot S, Macon-Lemaitre L, Paris E, Kobata T, Tanaka Y, Morimoto C, et al. B cell co-receptors regulating T cell-dependent antibody production in common variable immunodeficiency: CD27 pathway defects identify subsets of severely immuno-compromised patients. Int Immunol 2001; 13(7): 871-6.
  11. Geffroy-Luseau A, Jego G, Bataille R, Campion L, Pellat-Deceunynck C. Osteoclasts support the survival of human plasma cells in vitro. Int Immunol 2008; 20(6): 775-82.
  12. Mouillot G, Carmagnat M, Gerard L, Garnier JL, Fieschi C, Vince N, et al. B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol 2010; 30(5): 746-55.
  13. Nutt SL, Taubenheim N, Hasbold J, Corcoran LM, Hodgkin PD. The genetic network controlling plasma cell differentiation. Semin Immunol 2011; 23(5): 341-9.
  14. Kuo TC, Shaffer AL, Haddad J, Jr., Choi YS, Staudt LM, Calame K. Repression of BCL-6 is required for the formation of human memory B cells in vitro. J Exp Med 2007; 204(4): 819-30.
Journal of Isfahan Medical School
Volume 35, Issue 432 - Serial Number 432
March and April 2017
Pages 629-634

Files

History

  • Receive Date: 22 February 2017
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics